Tocolysis with nifedipine versus atosiban and perinatal outcome: an individual participant data meta-analysis
Tóm tắt
Worldwide, nifedipine and atosiban are the two most commonly used tocolytic agents for the treatment of threatened preterm birth. The aim of this study was to evaluate the effectiveness of nifedipine and atosiban in an individual participant data meta-analysis (IPDMA). We investigated the occurrence of adverse neonatal outcomes in women with threatened preterm birth by performing an IPDMA, and sought to identify possible subgroups in which one treatment may be preferred. We searched PubMed, Embase, and Cochrane for trials comparing nifedipine and atosiban for treatment of threatened preterm birth between 240/7 and 340/7 weeks’ gestational age. Primary outcome was a composite of perinatal mortality and neonatal morbidities including respiratory distress syndrome, intraventricular haemorrhage, periventricular leucomalacia, necrotising enterocolitis, and sepsis. Secondary outcomes included NICU admission, prolongation of pregnancy and GA at delivery. For studies that did not have the original databases available, metadata was used. This led to a two-stage meta-analysis that combined individual participant data with aggregate metadata. We detected four studies (N = 791 women), of which two provided individual participant data (N = 650 women). The composite neonatal outcome occurred in 58/364 (16%) after nifedipine versus 69/359 (19%) after atosiban (OR 0.76, 95%CI 0.47–1.23). Perinatal death occurred in 14/392 (3.6%) after nifedipine versus 7/380 (1.8%) after atosiban (OR 2.0, 95%CI 0.80–5.1). Nifedipine results in longer prolongation of pregnancy, with a 18 days to delivery compared with 10 days for atosiban (HR 0.83 (96% CI 0.69–0.99)). NICU admission occurred less often after nifedipine (46%) than after atosiban (59%), (OR 0.32, 95%CI 0.14–0.75). The sensitivity analysis revealed no difference in prolongation of pregnancy for 48 hours (OR 1.0, 95% CI 0.73–1.4) or 7 days (OR 1.3, 95% CI 0.85–5.8) between nifedipine and atosiban. There was a non-significant higher neonatal mortality in the nifedipine-exposed group (OR 1.4, 95% CI 0.60–3.4). In this IPDMA, we found no differences in composite outcome between nifedipine and atosiban in the treatment of threatened preterm birth. However, the non-significant higher mortality after administering nifedipine warrants further investigation of the use of nifedipine as a tocolytic drug. We conducted this study according to a prospectively prepared protocol, registered with PROSPERO (the International Prospective Register of Systematic Reviews) under CRD42016024244.
Tài liệu tham khảo
Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: when? Where? Why? Lancet. 2005;365(9462):891–900.
Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller A-BB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162–72.
Organization WH. WHO recommendations on interventions to improve preterm birth outcomes: World Health Organization. p. 98.
Keirse MJNCNC. The history of tocolysis. BJOG an Int. J Obstet Gynaecol. 2003;110(s20):94–7.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement. Plos Med. 2009;6(7):e1000097.
Twisk JWR. Software for multilevel analysis. Applied Multilevel Analysis. Cambridge: Cambridge University Press; 2014. p. 769–76.
Gates S, Brocklehurst P. How should randomised trials including multiple pregnancies be analysed? BJOG An Int J Obstet Gynaecol. 2004;111(3):213–9.
Geraci M. Linear Quantile Mixed Models: The lqmm Package for Laplace Quantile Regression. J Stat Software. 2014;57:1–29. https://doi.org/10.18637/jss.v057.i13.
Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928.
Van Vliet EOG, Nijman TAJ, Schuit E, Heida KY, Opmeer BC, Kok M, et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet. 2016;387(10033):2117–24.
Salim R, Garmi G, Nachum Z, Zafran N, Baram S, Shalev E. Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstet Gynecol. 2012;120(1873-233X (Electronic):1323–31.
Al-Omari WR, Al-Shammaa HB, Al-Tikriti EM, Ahmed KW. Atosiban and nifedipine in acute tocolysis: a comparative study. Eur J Obstet Gynecol Reprod Biol. 2006;128(1–2):129–34.
Kashanian M, Akbarian AR, Soltanzadeh M. Atosiban and nifedipin for the treatment of preterm labor. Int J Gynecol Obstet. 2005;91(1):10–4.
van’t Hooft J, JMN D, Daly M, Williamson PR, Meher S, Thom E, et al. A core outcome set for evaluation of interventions to prevent preterm birth. Obstet Gynecol. 2016;127(1):49–58.
Nederlandse Vereniging voor Obstetrie en Gynaecologie. Richtlijn dreigende vroeggeboorte. https://richtlijnendatabase.nl/richtlijn/dreigende_vroeggeboorte/tocolyse_bij_dreigende_vroeggeboorte.html.
Winden T, Klumper J, Kleinrouweler CE, Tichelaar MA, Naaktgeboren CAC, Nijman TAT, et al. Effects of tocolysis with nifedipine or atosiban on child outcome: follow up of the APOSTEL III trial. BJOG. 2020;127(9):1129–37.
Furuhashi N, Tsujiei M, Kimura H, Yajima A. Effects of nifedipine on normotensive rat placental blood flow, placental weight and fetal weight. Gynecol Obstet Investig. 1991;32(1):1–3.
Lirette M, Holbrook RH, Katz M. Cardiovascular and uterine blood flow changes during nicardipine hcl tocolysis in the rabbit. Obstet Gynecol. 1987;69(1):79–82.
Harake B, Gilbert RD, Ashwal S, Power GG. Nifedipine: effects on fetal and maternal hemodynamics in pregnant sheep. Am J Obstet Gynecol. 1987;157(4):1003–8.
Blea CW, Barnard JM, Magness RR, Phernetton TM, Hendricks SK. Effect of nifedipine on fetal and maternal hemodynamics and blood gases in the pregnant ewe. Am J Obstet Gynecol. 1997;176(4):922–30.
Mari G, Kirshon B, Moise KJ, Lee W, Cotton DB. Doppler assessment of the fetal and uteroplacental circulation during nifedipine therapy for preterm labor. Am J Obstet Gynecol. 1989;161(6 PART 1):1514–8.
Pirhonen JP, Erkkola RU, Ekblad UU, Nyman L. Single dose of nifedipine in normotensive pregnancy: Nifedipine concentrations hemodynamic responses, and uterine and fetal flow velocity waveforms. Obstet Gynecol. 1990;76(5 I):807–11.
Guclu S, Saygili U, Dogan E, Demir N, Baschat AA. The short-term effect of nifedipine tocolysis on placental, fetal cerebral and atrioventricular Doppler waveforms. Ultrasound Obstet Gynecol. 2004;24(7):761–5.
De Heus R, Mulder EJH, Derks JB, Visser GHA. The effects of the tocolytics atosiban and nifedipine on fetal movements, heart rate and blood flow. J Matern Neonatal Med. 2009;22(6):485–90.
Vogel JP, Oladapo OT, Manu A, Gülmezoglu AM, Bahl R. New WHO recommendations to improve the outcomes of preterm birth. Lancet Glob Heal. 2015;3(10):e589–90.